BRAXF BRAXIA SCIENTIFIC CORP
- 0.005600
- -0.000500-8.20%
BRAXIA SCIENTIFIC CORP News
Braxia Scientific Reports Q3 Results
Braxia Scientific Reports Q3 2024 Financial Results
Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More
John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy The world seemed to come to a momentary halt on December 8, 1980, when news that John Lennon was
Braxia Scientific's Q2 2024: Cash Burn Over But Income Low, What's Next For Psychedelics Company?
Ontario-based Canadian psychedelics company Braxia Scientific Corp. (OTC:BRAXF) filed its interim financial statements and management discussion for the three and six months ended Sept. 30, 2023. Num
Braxia Scientific Reports Q2 Results
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety Psychedelics biotech Cybin (NYSE:CYBN) and UK-based Small Pharma (OTC:DMTTF) announced their definitive arr
Braxia Scientific Faces Challenges In Accessing Public Market Capital, Reports Q1 Loss
Braxia Scientific Corp. (OTC:BRAXF), owner of ketamine therapy clinics and KetaMD telemedicine services for depression and related disorders, has shared its interim financial statements for the three
Braxia Scientific Reports FQ1 Results
Braxia Scientific Reports FY Results
Psyched: Dubai Psychedelics Event, Key Receptor Discovered, Drew Barrymore, Oprah's Guest, Swiss MDMA & More
Science Conference In Dubai, UAE Hosts Discussion On Psychedelics Research A milestone in psychedelics education was achieved: The Energia Foundation, organizer of the same conversation within this Ja
BetterLife's Non-Hallucinogenic LSD's Clinical Studies, Braxia's Psychedelic Treatments Continue
Psychedelics biotech BetterLife Pharma (OTCQB:BETRF) announced its non-hallucinogenic LSD derivative, BETR-001, is progressing through IND-enabling studies toward expected clinical studies targeting
Major Ketamine Clinics Chain Decides Not To Pursue Acquisition Deal
Irwin Naturals Inc. (OTC:IWINF) has terminated the non-binding amended and restated letter of intent (LOI) for a business combination with medical research and telemedicine company Braxia Scientific C
Update on LOI for Business Combination With Braxia Scientific Corp.
LOS ANGELES, March 16, 2023 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) ("Irwin" or the "Company"), announced today that it has terminated the non-binding amended and
Express News | Irwin Naturals Brief: Says Has Terminated Non-binding Amended and Restated Letter of Intent for a Business Combination With Braxia Scientific Corp.
SETTLEMENT OF BRAXIA SCIENTIFIC CORP. SECURITIES CLASS ACTION
Braxia Scientific's Q3 2023 Finances, Update On Upcoming Acquisition With Irwin Naturals
Research and telemedicine company Braxia Scientific Corp. (OTC:BRAXF) has filed its financial statements for the third quarter ended Dec. 31, 2022, and shared an update on its proposed acquisition by
Irwin Naturals Acquires Ketamine Clinic In Kentucky Adding $3M In Projected EBITDA
Irwin Naturals Inc. (OTCQB:IWINF) (CSE:IWIN) (FRA:97X) has successfully completed the acquisition of Serenity Health, LLC, a ketamine clinic in Louisville, KY. The agreement with Serenity was initiall
Irwin Naturals Signs LOI To Acquire Braxia Scientific Expanding Its Network Of Mental Health Clinics
Irwin Naturals Inc. (OTCQB:IWINF) (CSE:IWIN) (FRA:97X), has entered into a non-binding amended and restated letter of intent for a business combination with Braxia Scientific Corp.(OTCPK:BRAXF) (CSE:B
6 Psychedelics Companies Take Action: Here Are The Latest, Major Announcements
Second week of 2023, and business is up and running. Let's take a look at the announcements shared by some of the companies in the psychedelics space. Jaguar Health and Filament Health Form JV Jaguar
Braxia Scientific Q2 2023 Financial Results: Health Clinic Ketamine Treatments Increases 34.5% YoY
Braxia Scientific Corp., (CSE:BRAX) (OTC:BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related
Analysis
Price Target
No Data
